The development of an effective infectious
hematopoietic necrosis virus (IHNV) vaccine depends on a
better understanding of the antigenic structure and
variation among isolates. Three objectives to elucidate
this were: (1) to generate a panel of antigenic
derivatives of the IHNV glycoprotein by monoclonal
antibody-mediated selection of neutralization-resistant
variant viruses,...